BIMEKIZUMAB-BKZX: 5,360 Adverse Event Reports & Safety Profile
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
5,360
Total FAERS Reports
43 (0.8%)
Deaths Reported
397
Hospitalizations
5,360
As Primary/Secondary Suspect
22
Life-Threatening
17
Disabilities
Prescription
Status
FDA Application: 761151 ·
First Report: 20050822 · Latest Report: 20250915
What Are the Most Common BIMEKIZUMAB-BKZX Side Effects?
#1 Most Reported
Product dose omission issue
694 reports (12.9%)
#2 Most Reported
Psoriasis
621 reports (11.6%)
#3 Most Reported
Drug ineffective
402 reports (7.5%)
All BIMEKIZUMAB-BKZX Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Product dose omission issue | 694 | 13.0% | 0 | 24 |
| Psoriasis | 621 | 11.6% | 0 | 9 |
| Drug ineffective | 402 | 7.5% | 0 | 11 |
| Product availability issue | 364 | 6.8% | 0 | 17 |
| Off label use | 335 | 6.3% | 3 | 39 |
| Psoriatic arthropathy | 301 | 5.6% | 0 | 15 |
| Injection site pain | 263 | 4.9% | 0 | 8 |
| Therapy interrupted | 252 | 4.7% | 0 | 15 |
| Hidradenitis | 233 | 4.4% | 0 | 14 |
| Inappropriate schedule of product administration | 214 | 4.0% | 0 | 11 |
| Incorrect dose administered | 209 | 3.9% | 0 | 5 |
| Oral candidiasis | 178 | 3.3% | 0 | 9 |
| Pain | 159 | 3.0% | 1 | 5 |
| Fatigue | 148 | 2.8% | 0 | 6 |
| Headache | 146 | 2.7% | 0 | 7 |
| Pruritus | 146 | 2.7% | 0 | 7 |
| Rash | 135 | 2.5% | 0 | 5 |
| No adverse event | 122 | 2.3% | 0 | 0 |
| Candida infection | 116 | 2.2% | 0 | 3 |
| Condition aggravated | 115 | 2.2% | 0 | 9 |
Who Reports BIMEKIZUMAB-BKZX Side Effects? Age & Gender Data
Gender: 62.8% female, 37.2% male. Average age: 50.4 years. Most reports from: US. View detailed demographics →
Is BIMEKIZUMAB-BKZX Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2005 | 1 | 0 | 1 |
| 2020 | 5 | 0 | 5 |
| 2021 | 3 | 0 | 3 |
| 2022 | 11 | 2 | 7 |
| 2023 | 91 | 1 | 18 |
| 2024 | 1,346 | 9 | 112 |
| 2025 | 1,496 | 16 | 162 |
What Is BIMEKIZUMAB-BKZX Used For?
| Indication | Reports |
|---|---|
| Psoriasis | 3,059 |
| Psoriatic arthropathy | 1,033 |
| Product used for unknown indication | 716 |
| Hidradenitis | 598 |
| Ankylosing spondylitis | 199 |
| Off label use | 199 |
| Axial spondyloarthritis | 55 |
| Rheumatoid arthritis | 39 |
| Dermatitis atopic | 31 |
| Illness | 21 |
BIMEKIZUMAB-BKZX vs Alternatives: Which Is Safer?
BIMEKIZUMAB-BKZX vs BINIMETINIB
BIMEKIZUMAB-BKZX vs BIOFLAVONOIDS
BIMEKIZUMAB-BKZX vs BIOTIN
BIMEKIZUMAB-BKZX vs BIPERIDEN
BIMEKIZUMAB-BKZX vs BIRCH TRITERPENES
BIMEKIZUMAB-BKZX vs BISACODYL
BIMEKIZUMAB-BKZX vs BISACODYL OR DOCUSATE
BIMEKIZUMAB-BKZX vs BISMUTH
BIMEKIZUMAB-BKZX vs BISMUTH SUBCITRATE
BIMEKIZUMAB-BKZX vs BISMUTH SUBCITRATE\METRONIDAZOLE\TETRACYCLINE
Official FDA Label for BIMEKIZUMAB-BKZX
Official prescribing information from the FDA-approved drug label.